CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER (CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER).
Parenteral nutrition providing amino acids for protein synthesis and dextrose for caloric support, bypassing gastrointestinal tract.
| Metabolism | Amino acids undergo hepatic metabolism via deamination and transamination; dextrose undergoes glycolysis and oxidative phosphorylation. |
| Excretion | Renal: ~50% as unchanged amino acids and dextrose metabolites within 6 hours; remainder metabolized to CO2 and H2O, eliminated via lungs and urine. |
| Half-life | Not applicable; components are endogenously regulated (amino acids: minutes to hours; dextrose: ~1-2 hours). For continuous infusion, steady-state achieved within 4-6 hours. |
| Protein binding | Minimal (<10%) for amino acids and dextrose; no specific binding proteins. |
| Volume of Distribution | Not determined for fixed combination; individual components distribute rapidly (amino acids: ~0.3-0.5 L/kg; dextrose: ~0.2 L/kg, confined to extracellular fluid). |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: Immediate (within minutes) for caloric support and nitrogen balance. |
| Duration of Action | Continuous infusion: effect persists as long as infusion continues; after cessation, metabolic effects diminish over 1-2 hours. |
Intravenous administration of 2.75% amino acids and 10% dextrose at a rate to provide 1-2 g protein/kg/day and 5-25 g dextrose/kg/day based on metabolic needs. Infusion rate not to exceed 0.5 g dextrose/kg/hour initially.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: Reduce protein intake to 0.6-0.8 g/kg/day. GFR 30-60 mL/min: Adjust protein to 0.8-1.0 g/kg/day. Monitor renal function and electrolytes closely. |
| Liver impairment | Child-Pugh B or C: Restrict total protein to 0.5-1.0 g/kg/day with caution for encephalopathy. Use amino acid formulations enriched in branched-chain amino acids if available. |
| Pediatric use | Weight-based dosing: 2-3 g amino acids/kg/day and 10-20 g dextrose/kg/day. Infusion rate titrate to glucose tolerance, not to exceed 0.5 mg/kg/min dextrose initially for neonates. |
| Geriatric use | Elderly: Use lower end of protein range (1-1.2 g/kg/day) due to renal decline. Monitor fluid and electrolyte status closely, avoid fluid overload with rate adjustments. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER (CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER).
| Breastfeeding | Amino acids and dextrose are normal constituents of breast milk. Exogenous administration is unlikely to significantly alter milk composition. M/P ratio not applicable as they are endogenous substances. Generally compatible with breastfeeding if clinically indicated. |
| Teratogenic Risk | Amino acids and dextrose are endogenous nutrients; no teratogenic risk is anticipated at standard doses. However, use in pregnancy requires careful nutritional management. No trimester-specific risks identified from the formulation. |
■ FDA Black Box Warning
Not for intravenous infusion in patients with sulfite sensitivity (contains metabisulfite). Risk of allergic reactions including anaphylaxis.
| Serious Effects |
["Sulfite allergy","Severe hyperglycemia or hyperlactatemia","Uncontrolled metabolic acidosis","Hepatic coma","Anuria or severe renal failure without dialysis"]
| Precautions | Monitor for hyperglycemia, electrolyte imbalances, fluid overload, and infection risk from catheter. Use caution in renal/hepatic impairment. Aluminum toxicity risk with prolonged use. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, blood glucose, acid-base status, fluid balance, and renal function. Assess fetal growth and well-being via ultrasound if parenteral nutrition is prolonged. |
| Fertility Effects | No known adverse effects on fertility from amino acids or dextrose. Infertility may be related to underlying disease requiring parenteral nutrition. |